Protalix BioTherapeutics Stock Price - PLX

3.18
-0.11 (-3.34%)
Upgrade to Real-Time
Regular Market
3.18
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Protalix BioTherapeutics Inc PLX AMEX Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.11 -3.34% 3.18 3.14 3.37 3.33 3.29 11:06:25
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
349 107,917 $ 3.30 $ 356,449 268,161 0.17 - 5.00
Last Trade Time Type Quantity Stock Price Currency
11:06:24 400 $ 3.18 USD

Protalix BioTherapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 104.47M 32.44M 27.91M $ 54.69M $ -13.61M -1.13 -7.68
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
1.26M $ - 0.00% 1.00 14.00%

more financials information »

Protalix BioTherapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PLX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.943.512.853.13219,5740.248.16%
1 Month4.454.8652.813.26307,770-1.27-28.54%
3 Months3.284.8652.03623.17204,059-0.10-3.05%
6 Months0.28955.000.23751.94295,0282.89998.45%
1 Year0.395.000.170.7763298495,9322.79715.38%
3 Years0.925.000.170.6583519637,4492.26245.65%
5 Years2.145.000.170.7741046773,5771.0448.6%

Protalix BioTherapeutics Description

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa, for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. Its pipeline products include Alidornase Alfa, Pegunigalsidase Alfa, and Oprx-106. The company's primary sources of revenues include its sales of taliglucerase alfa in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.


Your Recent History
AMEX
PLX
Protalix B..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.